Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?

Journal Title: Viral Hepatitis Journal - Year 2018, Vol 24, Issue 3

Abstract

Objectives: Pegylated-interferon (Peg-IFN) alpha 2a/2b and nucleoside and/or nucleotide analogues (NAs) are currently the only two treatment approaches approved for the chronic hepatitis B (CHB). To date, few studies have compared Peg-IFN with NAs in the treatment of CHB. We aimed in this study to evaluate the effectiveness of Peg-IFN and potent NAs (entecavir and tenofovir disoproxil) and to compare cumulative virological and serological responses in Turkish CHB patients treated between 2006 and 2016. Materials and Methods: In this observational retrospective study, we divided a total of 331 patients, who were diagnosed with CHB, into 3 groups: Peg-IFN treatment group (n=62), entecavir treatment group (n=131) and tenofovir disoproxil treatment group (n=138). Results: Virologic response rate in the Peg-IFN treatment group (90%) at 12 months was higher than in the NAs treatment groups (80% for entecavir and 76% for tenofovir disoproxil) (p<0.05). Sustained virologic response (SVR) rate at 24 months was 61% in the Peg-IFN group (p<0.001). The rate of hepatitis B e antigen seroconversion was significantly higher in the Peg-IFN group (25%) than in the NAs groups (16% for entecavir, 13% for tenofovir disoproxil). Hepatitis B surface antigen (HBsAg) seroconversion rate was also higher in the Peg-IFN than in the NAs treatment groups (7.9% vs. 0.9% and 0%, respectively) (p<0.001). After HBsAg seroconversion, the titers of anti-HBs were retained for over six months. Conclusion: Peg-IFN treatment was found to be effective with high SVR and hepatitis B e antigen and HBsAg seroconversion rates than NAs treatment in long-term follow-up of patients with CHB. Peg-IFN appears to be the first-choice treatment approach in patients with CHB until a new era in which hepatitis B is cured.

Authors and Affiliations

Figen SARIGÜL YILDIRIM, Ülkü USER, Murat SAYAN, Nefise ÖZTOPRAK

Keywords

Related Articles

Analysis of Virological, Histological and Clinical Features of Hepatitis Delta Virus Infection in Southeastern Turkey

Objectives: The present study aims to investigate biochemical, virological and histological characteristics of hepatitis delta virus infection, which is a serious problem in our region, as well as its relationship with c...

TNF-alpha 308 SNP Rs3091256 GG Genotype is Strongly Associated with Fibrosis in Patients with Chronic Hepatitis C

Objective: We aimed to review the influence of host genetic factors on the clinical course, treatment response as well as fibrosis progression in patients with viral hepatitis C genotype 1. Materials and Methods: Ninety...

Investigation of Mean Platelet Volume, Platelet Distribution Width and Erythrocyte Distribution Width in Patients with Hepatitis B Virus Infection

Objective: Hepatitis B virus (HBV) infection is an important public health issue all over the world, and it has a high morbidity and mortality rates caused by chronic liver disease. Liver biopsy is the primary procedure...

Download PDF file
  • EP ID EP427189
  • DOI 10.4274/vhd.2018.0006
  • Views 69
  • Downloads 0

How To Cite

Figen SARIGÜL YILDIRIM, Ülkü USER, Murat SAYAN, Nefise ÖZTOPRAK (2018). Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. Viral Hepatitis Journal, 24(3), 90-95. https://europub.co.uk/articles/-A-427189